2) Cain AE, Khalil RA:Pathophysiology of essential hypertension:role of the pump, the vessel and the kidney. Semin Nephrol 22:3-16, 2002
7) Lithell H, Hansson L, Skoog I et al:The Study on Cognition and Prognosis in the Elderly (SCOPE):principal results of a randomized double-blind intervention trial. J Hypertens 21:875-886, 2003
11) Flather MD, Yusuf S, Kφber L et al:Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction:a systemic overview of data from individual patients. Lancet 355:1575-1581, 2000
18) Gansevoort RT, Mimran A, de Zeeuw D et al:AT1 receptor antagonists and the kidney. In:Angiotensin II Receptor Antagonists, (ed by Epstein M, Brunner HR), Hanley & Belfus, Inc., Philadelphia, 2001, pp 295-316
19) Burns KD:Angiotensin II and its recaptors in the diabetic kidney. Am J kidney Dis 36:449-467, 2000
27) Heart Outcomes Prevention Evaluation (HOPE) Study Investigators:Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus:results of the HOPE study and MICRO-HOPE substudy. Lancet 355:253-259, 2000
28) Hansson L, Lindholm LH, Niskanen L et al:Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension:the Captopril Prevention Project (CAPPP) randomised trial. Lancet 353:611-616, 1999